Cure My Disease

Don't miss your cure!

 Log in / Sign up

Measles virus takes on ovarian cancer in early trial

NCT ID NCT02364713

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy cells alone. The study was terminated early, so firm conclusions about effectiveness are not possible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
genetically modified measles virus (MV-NIS)
What this could lead to
If successful, this could point toward a new treatment option for ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong
This trial was terminated early with only 17 participants, so results are very limited. The virus may not work better than standard chemotherapy and could cause side effects like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma fallopian tube carcinosarcoma fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube mucinous adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma fallopian tube transitional cell carcinoma ovarian cancer ovarian carcinoma ovarian carcinosarcoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous adenocarcinoma ovarian seromucinous carcinoma ovarian serous adenocarcinoma ovarian transitional cell carcinoma primary peritoneal carcinoma primary peritoneal serous adenocarcinoma undifferentiated carcinoma undifferentiated ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CARCINOSARCOMA FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA FALLOPIAN TUBE SEROUS ADENOCARCINOMA FALLOPIAN TUBE TRANSITIONAL CELL CARCINOMA FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA OVARIAN CARCINOSARCOMA OVARIAN CLEAR CELL ADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN MUCINOUS ADENOCARCINOMA OVARIAN SEROMUCINOUS CARCINOMA OVARIAN SEROUS ADENOCARCINOMA OVARIAN TRANSITIONAL CELL CARCINOMA OVARIAN UNDIFFERENTIATED CARCINOMA PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA PLATINUM-RESISTANT OVARIAN CARCINOMA PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA PRIMARY PERITONEAL CARCINOSARCOMA PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA PRIMARY PERITONEAL SEROUS ADENOCARCINOMA PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.